7,506 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Summit Global Investments

Summit Global Investments acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 7,506 shares of the biopharmaceutical company’s stock, valued at approximately $4,680,000.

Other large investors have also recently added to or reduced their stakes in the company. WPG Advisers LLC grew its holdings in shares of Regeneron Pharmaceuticals by 312.5% during the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 25 shares in the last quarter. SHP Wealth Management purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $26,000. Western Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth $26,000. Titan Wealth CI Ltd acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $29,000. Finally, Kemnay Advisory Services Inc. acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $31,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the transaction, the director directly owned 17,303 shares in the company, valued at approximately $11,249,545.45. This represents a 1.14% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 1,400 shares of company stock worth $1,090,030. 6.97% of the stock is currently owned by insiders.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron is expanding its oncology relationship with Biohaven through a clinical supply agreement to test Biohaven’s BHV-1530 alongside Regeneron’s Libtayo in patients with solid tumors. The combination could strengthen Regeneron’s oncology pipeline if clinical results are favorable. Biohaven-Regeneron Oncology Deal
• Positive Sentiment: Regeneron also entered a strategic research collaboration with Parabilis Medicines to develop antibody-Helicon conjugates. The agreement includes $125 million in upfront consideration and equity investment for Parabilis, with potential milestone payments of up to $2.2 billion plus royalties—highlighting Regeneron’s efforts to broaden its technology base and future pipeline. Parabilis Medicines-Regeneron Collaboration
• Neutral Sentiment: Coverage highlights Regeneron’s exposure to GLP-1-related growth opportunities beyond the leading weight-loss drug makers, although the article provides limited new company-specific financial information. GLP-1 Demand and Regeneron
• Neutral Sentiment: Director Kathryn Guarini sold $320,000 of REGN stock under a pre-arranged Rule 10b5-1 trading plan. Because the sale was scheduled in advance, it is a limited indicator of management’s current outlook.
• Negative Sentiment: Multiple law firms are promoting a securities class action against Regeneron concerning alleged disclosures about the Phase 3 fianlimab-Libtayo melanoma trial. The trial’s failure reportedly erased approximately $11 billion in market value, and the continuing legal notices may keep investor attention focused on potential litigation costs, disclosure risks and weakness in the oncology program. The lead-plaintiff deadline is September 14, 2026. Regeneron Class Action Lawsuit

Regeneron Pharmaceuticals Trading Down 0.3%

Regeneron Pharmaceuticals stock opened at $803.48 on Friday. Regeneron Pharmaceuticals, Inc. has a one year low of $541.00 and a one year high of $821.11. The company’s fifty day moving average price is $675.79 and its two-hundred day moving average price is $714.34. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The company has a market capitalization of $82.73 billion, a price-to-earnings ratio of 19.86, a PEG ratio of 1.37 and a beta of 0.22.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $12.81 earnings per share. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.29%.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on REGN shares. Canaccord Genuity Group dropped their target price on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research report on Tuesday, May 19th. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 24th. Wall Street Zen raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Piper Sandler dropped their price objective on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a report on Thursday, July 9th. Finally, Cantor Fitzgerald raised their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Sixteen analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $793.74.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.